Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methyldopa (Racemic). The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.97 |
| ▸ | MAPT | P10636 | 6/20 | 0.97 |
| ▸ | BLM | P54132 | 5/20 | 0.97 |
| ▸ | HPGD | P15428 | 4/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.97 |
| ▸ | RECQL | P46063 | 4/20 | 0.97 |
| ▸ | POLB | P06746 | 3/20 | 0.97 |
| ▸ | GAA | P10253 | 3/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.97 |
| ▸ | APEX1 | P27695 | 3/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | USP2 | O75604 | 2/20 | 0.97 |
| ▸ | EGFR | P00533 | 2/20 | 0.97 |
| ▸ | FYN | P06241 | 2/20 | 0.97 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyldopa SCHEMBL2491162 | 1.00 | KDM4E (0.97) | KDM4ETDP1HSD17B10MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL2494131 | 0.98 | KDM4E (0.94) | KDM4ETDP1HSD17B10MAPTBLM | |
| Methyldopa SCHEMBL6825739 | 0.98 | KDM4E (0.94) | KDM4ETDP1HSD17B10MAPTBLM | |
| Methyldopa SCHEMBL11448470 | 0.98 | KDM4E (0.94) | KDM4ETDP1HSD17B10MAPTBLM | |
| Methyldopa SCHEMBL29352376 | 0.98 | KDM4E (1.00) | KDM4ETDP1HSD17B10MAPTBLM | |
| Methyldopa SCHEMBL30176814 | 0.98 | KDM4E (1.00) | KDM4ETDP1HSD17B10MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL196981 | 0.98 | KDM4E (1.00) | KDM4ETDP1HSD17B10MAPTBLM | |
| Methyldopa SCHEMBL1321546 | 0.98 | KDM4E (1.00) | KDM4ETDP1HSD17B10MAPTBLM | |
| Methyldopa SCHEMBL1172822 | 0.98 | KDM4E (1.00) | KDM4ETDP1HSD17B10MAPTBLM | |
| Methyldopa SCHEMBL34003 | 0.98 | KDM4E (1.00) | KDM4ETDP1HSD17B10MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107137338-B | Hair dyeing method based on surface coating principle | 苏州蓬拓生物医学科技有限公司 | 2021-04-06 | — | — | CN | claimed |
| WO-2013067591-A1 | TOPICAL FORMULATIONS FOR PAIN MANAGEMENT | RELEVARE AUSTRALIA PTY LTD (AU) | 2013-05-16 | — | — | WO | claimed |
| JP-4800219-B2 | — | — | 2011-10-26 | — | — | JP | claimed |
| EP-1701725-A4 | METHODS AND COMPOSITIONS | CNSBIO PTY LTD (AU) | 2009-07-01 | — | — | EP | claimed |
| EP-1701725-A1 | METHODS AND COMPOSITIONS | CNSBIO PTY LTD (AU) | 2006-09-20 | — | — | EP | claimed |
| WO-2005058319-A1 | METHODS AND COMPOSITIONS | CNSBIO PTY LTD (AU) | 2005-06-30 | — | — | WO | claimed |
| CN-107137338-B | Hair dyeing method based on surface coating principle | 苏州蓬拓生物医学科技有限公司 | 2021-04-06 | — | — | CN | disclosed |
| US-20200197315-A1 | ORAL DOSAGE FORM WITH DRUG COMPOSITION, BARRIER LAYER AND DRUG LAYER | ORIENT PHARMA CO., LTD. (TW) | 2020-06-25 | — | — | US | disclosed |
| US-10646444-B2 | Method of preparing biologically formulations active | NORTEC DEVELOPMENT ASSOCIATES, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200101021-A1 | ORAL PHARMACEUTICAL DOSAGE FORMS | DURECT CORPORATION (US) | 2020-04-02 | — | — | US | disclosed |
| US-20190231702-A1 | Oral Pharmaceutical Dosage Forms | DURECT CORP (US) | 2019-08-01 | — | — | US | disclosed |
| US-10300142-B2 | Compositions with a rheological modifier to reduce dissolution variability | DURECT CORPORATION (US) | 2019-05-28 | — | — | US | disclosed |
| US-10206883-B2 | Oral pharamaceutical dosage forms | DURECT CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-4684524-A | Rate controlled dispenser for administering beneficial agent | ALZA CORPORATION (US) | 1987-08-04 | — | — | US | disclosed |
| US-4627850-A | Osmotic capsule | ALZA CORPORATION (US) | 1986-12-09 | — | — | US | disclosed |
| US-4624945-A | Dispensing system with means for increasing delivery of beneficial agent from the system | ALZA CORPORATION (US) | 1986-11-25 | — | — | US | disclosed |
| US-4612008-A | Osmotic device with dual thermodynamic activity | ALZA CORPORATION (US) | 1986-09-16 | — | — | US | disclosed |
| EP-0052917-B1 | OSMOTIC DEVICE WITH HYDROGEL DRIVING MEMBER | ALZA CORPORATION (US) | 1985-09-18 | — | — | EP | disclosed |
| EP-0052917-A2 | Osmotic device with hydrogel driving member | ALZA CORPORATION (US) | 1982-06-02 | — | — | EP | disclosed |
| US-4327725-A | Osmotic device with hydrogel driving member | ALZA CORPORATION (US) | 1982-05-04 | — | — | US | disclosed |